Full-Time

Director – Rheumatology Medical Engagement Lead

Confirmed live in the last 24 hours

Deadline 7/31/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$275k - $334k/yr

+ Incentive Cash + Stock Opportunities

Expert

Company Historically Provides H1B Sponsorship

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • 10+ years of relevant experience
  • MD from top clinical practice and hospital-academic centers
  • Proven record of developing high impact peer-to-peer relationships and influence with high impact National Thought Leaders
  • Strong Rheumatology experience required: scientific or clinical area, patient treatment trends, clinical landscape, pharmaceutical industry, including compliance and regulatory guidelines, clinical trial design and process, national and regional healthcare and access environment
  • Working in a scientific and/or clinical research environment
  • Deep understanding of National Thought Leaders’ environment and needs.
Responsibilities
  • Engaging in high-quality peer-to-peer scientific dialog with key National Thought Leaders in Rheumatology focused on pre- and peri-launch period
  • Collaborates with National Thought Leaders to identify and generate insights on evolving care paradigms to inform medical strategy
  • Provides strategic input into materials for national medical congresses
  • Facilitates scientific partnerships and research collaborations in collaboration with Global Drug Development (GDD)
  • Provides recommendations and insights to the clinical development team on study feasibilities within the therapeutic area based on knowledge of the field and through direct contacts with potential investigators, as agreed with home office medical and Global Development Operations (GDO)
  • Proactively leads BMS major evidence readouts to investigators partnering with GDD
  • Reactively discuss major evidence readouts with other thought-leaders
  • Liaises with large key accounts to understand clinical levers and barriers to patient access in the context of clinical trials
  • Effectively collaborates and communicates with National Thought Leaders to gain insights into the clinical landscape
  • Engages in scientific and clinical conversation to ensure the development of a product/disease area-focused medical plan that translates into effective launch and Life Cycle Maintenance (LCM) activities
  • Responsible for conducting evidence read-outs with the most prominent institutions, e.g., Phase 3 top-line data
  • Engages with medical societies, Patient Advocacy Groups, and guideline discussions as appropriate
  • Engage account-level decision makers in selected Academic Medical Centers to help identify barriers and solutions to improve patient care and outcomes.
Desired Qualifications
  • Ability to engage in a peer-to-peer dialog about data in a fair and balanced way
  • Expert knowledge of clinical practice and evolving healthcare delivery models
  • Ability to understand and critically appraise scientific publications
  • Knowledge of clinical trial design and methodology, including Good Clinical Practices and ethical, governmental, and regulatory requirements
  • Understands treatment paradigms and can frame information in a convincing way that resonates with physicians
  • Excellent communication and presentation skills to articulate scientific and clinical data in an easy-to-understand manner to help HCPs best serve their patients
  • Has a strong learning mindset and passion for science. Prioritizes staying current with the latest data
  • Understands the patient journey and experience
  • Able to adopt a patient-focused mindset, making patients a top priority
  • Exhibits genuine care for patients
  • Winning Mindset: results-oriented, positive, resilient attitude, able to quickly adapt in an ever-changing environment
  • Demonstrated ability to drive organizational performance
  • Experience identifying, engaging, and cultivating relationships with TLs
  • Demonstrated an ability to influence matrix organization and problem-solving mentality
  • Ability to work independently and act as a team player by developing strong rapport and working relationships with external and internal stakeholders
  • Knowledge of the national healthcare and access environments
  • Deep knowledge and experience of RWE
  • Be a representative of BMS in all interactions with external stakeholders
  • Holds a high level of integrity and good judgment, in order to navigate the requirements of the role effectively and compliantly in accordance with BMS policies and procedures.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medications, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnership with BioNTech to develop next-gen cancer therapies enhances competitive edge.
  • Increased use of real-world data (RWD) improves drug development and patient outcomes.
  • Commitment to sustainability and ESG goals strengthens corporate reputation and stakeholder trust.

What critics are saying

  • Partnership with BioNTech may face challenges if cancer therapies don't meet expectations.
  • Reliance on RWD could delay new therapies if integration is ineffective.
  • Recent layoffs may disrupt operations and affect employee morale, impacting productivity.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

Hit Consultant
Jun 10th, 2025
From Raw Records To Real-Time Insights: Climbing Pharma’S Real-World Data Maturity Curve

Viraj Narayanan, CEO at Cornerstone AI Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers SquibbReal-world data (RWD) has become the pharmaceutical industry’s most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and repeatable approach to data quality, as well as a strategic roadmap that moves an organization from minimal use of RWD to a position of true leadership. This journey isn’t simple, but for those committed to navigating it, the competitive advantages are substantial. And, importantly, RWD holds the potential to help bring lifesaving and life-changing medications to market faster and safer than ever before.From Data Collection to MaturityPharma’s growing reliance on RWD has encouraged an influx of partnerships with data aggregators, medical institutions, and digital health platforms. Yet, not all companies are at the same level of maturity in using that data effectively

Devdiscourse
Jun 2nd, 2025
Reuters Health News Summary

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

The Motley Fool
Jun 2nd, 2025
Why BioNTech Stock Soared Today

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327.

Pharmaceutical Executive
Jun 2nd, 2025
Bristol Myers Squibb, BioNTech Partner to Develop Next-Gen Bispecific Antibody for Solid Tumors

Bristol Myers Squibb, BioNTech partner to develop next-gen Bispecific Antibody for solid tumors.